Not recruiting
Migraine
Not recruitingRegistered drug
Study on Lasmiditan for Treating Migraine in Children Aged 6 to 17
Registered drug
- Disease:Migraine
- Substances:Lasmiditan
Countries:
Germany
Germany- Participants:0–17 years
- Substances:Lasmiditan
Find therapies in clinical trials near you – page 18
- recruiting
- 3 962
- countries
- 28
- conditions
- 2 101
3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today
250 trials match your criteria
Not recruiting
Type 1 diabetes mellitus
Not recruitingRegistered drugNo placebo
Study on Insulin Lispro and Insulin Human for Managing Blood Sugar After Meals in Type 1 Diabetes Patients with Different Gastric Emptying Rates
Registered drugNo placebo
- Disease:Type 1 diabetes mellitus
- Substances:Insulin Human (Rdna)Insulin Lispro
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Insulin Human (Rdna)
Not recruiting
Multiple sclerosis
Not recruitingRegistered drugNo placebo
Study on the Safety and Effectiveness of Fingolimod and Interferon Beta-1a in Children with Multiple Sclerosis
Registered drugNo placebo
- Disease:Multiple sclerosis
- Substances:Fingolimod
Countries:Germany
Germany- Participants:0–17 years
- Substances:Fingolimod
Not recruiting
Colon cancer stage II+1
Not recruitingRegistered drugNo placebo
Study on Adjuvant Therapy with Capecitabine for Stage II Colon and Rectal Cancer Patients with Positive ctDNA After Tumor Removal
Registered drugNo placebo
- Disease:Colon cancer stage IIRectal cancer stage II
- Substances:Capecitabine
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Capecitabine
Not recruiting
Multiple sclerosis+1
Not recruitingRegistered drugNo placebo
Study on B-Cell Levels in Infants Exposed to Ocrelizumab During Pregnancy for Mothers with Multiple Sclerosis or Clinically Isolated Syndrome
Registered drugNo placebo
- Disease:Multiple sclerosisClinically isolated syndrome
- Substances:Ocrelizumab
Countries:Germany
Germany- Participants:18–64 years
- Substances:Ocrelizumab
Not recruiting
Metastatic malignant melanoma
Not recruitingRegistered drugNo placebo
Study of IO102-IO103 and Pembrolizumab for Patients with Advanced Melanoma
Registered drugNo placebo
- Disease:Metastatic malignant melanoma
- Substances:Io102 HydrochloridePembrolizumab
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Io102 Hydrochloride
Not recruiting
Huntington's disease
Not recruitingInvestigational
Study on the Safety and Effects of PTC518 for Patients with Huntington's Disease
Investigational
- Disease:Huntington's disease
- Substances:Ptc518
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Ptc518
Not recruiting
Hidradenitis
Not recruitingInvestigational
Study on the Effectiveness of Ianalumab for Treating Moderate to Severe Hidradenitis Suppurativa in Patients
Investigational
- Disease:Hidradenitis
- Substances:Ianalumab
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Ianalumab
Not recruiting
Registered drug
Study on the Effectiveness and Safety of Nipocalimab for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Registered drug
- Disease:Chronic inflammatory demyelinating polyradiculoneuropathy
- Substances:NipocalimabHuman Normal Immunoglobulin
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Nipocalimab
Not recruiting
Hidradenitis
Not recruitingInvestigationalNo placebo
Study on the Long-Term Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa
InvestigationalNo placebo
- Disease:Hidradenitis
- Substances:4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
Not recruiting
Huntington's disease
Not recruitingInvestigational
Study on the Safety and Efficacy of Tominersen for Patients with Prodromal and Early Manifest Huntington's Disease
Investigational
- Disease:Huntington's disease
- Substances:Tominersen
Countries:Germany
Germany- Participants:18–64 years
- Substances:Tominersen
Not recruiting
Hypercholesterolaemia
Not recruitingRegistered drugNo placebo
Study Comparing Inclisiran and Bempedoic Acid for Lowering LDL Cholesterol in Patients with Atherosclerotic Cardiovascular Disease
Registered drugNo placebo
- Disease:Hypercholesterolaemia
- Substances:AtorvastatinBempedoic Acid+3
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Atorvastatin